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Abstract
Background: Angiogenesis is a critical early feature of atherosclerotic plaque development and may also feature
prominently in the pathogenesis of aortic valve stenosis. It has been shown that MRI can detect and quantify
specific molecules of interest expressed in cardiovascular disease and cancer by measuring the unique fluorine
signature of appropriately targeted perfluorocarbon (PFC) nanoparticles. In this study, we demonstrated specific
binding of ανβ3 integrin targeted nanoparticles to neovasculature in a rabbit model of aortic valve disease. We
also showed that fluorine MRI could be used to detect and quantify the development of neovasculature in the
excised aortic valve leaflets.
Methods: New Zealand White rabbits consumed a cholesterol diet for ~180 days and developed aortic valve
thickening, inflammation, and angiogenesis mimicking early human aortic valve disease. Rabbits (n = 7) were
treated with ανβ3 integrin targeted PFC nanoparticles or control untargeted PFC nanoparticles (n = 6).
Competitive inhibition in vivo of nanoparticle binding (n = 4) was tested by pretreatment with targeted
nonfluorinated nanoparticles followed 2 hours later by targeted PFC nanoparticles. 2 hours after treatment, aortic
valves were excised and 19F MRS was performed at 11.7T. Integrated 19F spectral peaks were compared using a
one-way ANOVA and Hsu's MCB (multiple comparisons with the best) post hoc t test. In 3 additional rabbits
treated with ανβ3 integrin targeted PFC nanoparticles, 19F spectroscopy was performed on a 3.0T clinical scanner.
The presence of angiogenesis was confirmed by immunohistochemistry.
Results: Valves of rabbits treated with targeted PFC nanoparticles had 220% more fluorine signal than valves of
rabbits treated with untargeted PFC nanoparticles (p < 0.001). Pretreatment of rabbits with targeted oil-based
nonsignaling nanoparticles reduced the fluorine signal by 42% due to competitive inhibition, to a level not
significantly different from control animals. Nanoparticles were successfully detected in all samples scanned at
3.0T. PECAM endothelial staining and ανβ3 integrin staining revealed the presence of neovasculature within the
valve leaflets.
Conclusion: Integrin-targeted PFC nanoparticles specifically detect early angiogenesis in sclerotic aortic valves
of cholesterol fed rabbits. These techniques may be useful for assessing atherosclerotic components of preclinical
aortic valve disease in patients and could assist in defining efficacy of medical therapies.
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Background
Aortic valve sclerosis is a common disease of the elderly,
occurring in approximately 30% of the population aged >
65 years. Sclerosis progresses to clinically significant val-
vular stenosis in approximately 2% of this population
[1,2]. Despite its prevalence, no medical treatment for
aortic stenosis (AS) has proven effective. For severe steno-
sis, surgical valve replacement is the preferred treatment;
however, many elderly AS patients are poor surgical can-
didates. Balloon valvuloplasty is a viable option for some
of these patients [3], but high rates of restenosis limit its
efficacy [4]. A medical treatment option would therefore
greatly benefit the patient population. Recent data from a
prospective study suggest that statin therapy very early in
the disease course may slow its progression, but the effi-
cacy was greatly reduced in patients who had moderate or
severe valvular stenosis at the time of the study [5]. This
clinical observation implies that early diagnosis of AS may
be the key to developing and applying effective medical
therapies.
Although AS was once considered a passive degenerative
process, its pathogenesis actually involves a chronic
inflammatory and immune-mediated response similar in
the earliest stages to atherosclerosis. Immunohistochem-
istry of excised human aortic valves has demonstrated
lipid deposition, endothelial damage, and infiltration by
activated T-cells. Upregulation of cell adhesion molecules
such as CD34, intercellular adhesion molecule 1 (ICAM-
1), vascular cell adhesion molecule 1 (VCAM-1), oste-
opontin, and platelet and endothelial cell adhesion mol-
ecule (PECAM) has been reported [5-9]. Upregulated
expression of extracellular matrix proteins such as metal-
loproteinases that are involved in the inflammatory
response and angiogenesis also has been reported [7].
Angiogenesis appears to play a key role in this pathologi-
cal process [6-9]. Angiogenesis is driven by local expres-
sion of cytokines and growth factors such as vascular
endothelial growth factor (VEGF), produced by the
expanding cellular infiltrate in the inflamed valve. Neo-
vasculature serves as a conduit for the delivery of yet more
inflammatory messengers and activated cells [8]. Ang-
iogenic vasculature is distinguished from mature vascula-
ture by marked and early upregulation of endothelial
integrins (e.g. ανβ3 integrin) and adhesion molecules that
are expressed in stages as the neovasculature matures.
The cholesterol-fed rabbit is a well-characterized model of
atherosclerosis [10]. It has been shown that, with a
slightly longer diet regimen, these rabbits develop aortic
valve sclerosis [11-13]. The histological changes observed
(gross thickening, macrophage infiltration, calcification,
and eventual bone formation) mimic the pathobiology of
human aortic stenosis [11-14]. Based on the similarities
between human and rabbit disease, we hypothesized that
ανβ3 integrin positive neovasculature would be present in
sclerotic rabbit aortic valve leaflets, and that it could be
detected noninvasively with MRI molecular imaging. Our
laboratory has developed perfluorocarbon nanoparticles
for MRI molecular imaging and targeted drug delivery. We
have demonstrated previously that ανβ3 -integrin targeted
nanoparticles bearing gadolinium chelates can be used to
image angiogenesis in atherosclerotic plaques of choles-
terol fed rabbits with proton MRI on a 1.5T clinical scan-
ner [15].
In this study, we sought to demonstrate ex vivo proof of
concept for specific nanoparticle binding to angiogenesis
in the sclerotic aortic valve leaflets of cholesterol fed rab-
bits, and for sensitive MRI/MRS detection of fluorine in
the nanoparticles. We proposed that by using the native
fluorine signal emanating from the perfluorocarbon core
of the particles, we could depict a unique MRI/MRS signa-
ture of angiogenesis, which is an important component of
the inflammatory process [16,17]. Compared to tradi-
tional proton-based molecular imaging [18], the benefits
of fluorine imaging and spectroscopy are multiple: 1) a
unique and specific signature for MRI molecular imaging
because 19F is found only in trace quantities in biological
tissues, 2) lack of background signal for the same reasons,
3) no need for both pre- and post-contrast images because
the signal is unique and specific, and 4) ability to perform
quantitative 19F NMR spectroscopy and potentially esti-
mate the concentration of molecular binding sites in a tar-
geted sample.
Methods
Animal preparation
Several groups have reported that rabbits placed on an
extended high-cholesterol diet develop gross thickening
of the aortic valve, with histological changes including
macrophage infiltration, fibrosis, and deposition of cal-
cific nodules [11-13]. Involvement of proteins such as
osteopontin and proliferating cell nuclear antigen
(PCNA) characteristic of human-type disease has also
been reported [14,19].
Twenty-six New Zealand White rabbits (Harlan, Indiana-
polis, Indiana) consumed a 0.25% cholesterol diet for 5
months to induce aortic valve disease. Normal controls
consisted of four male retired breeders (Myrtle's Rabbitry,
Thompson's Station, Tennessee) with similar body
weights to the cholesterol-fed group (approximately 4 kg).
Specimens from 17 cholesterol-fed rabbits and 3 healthy
controls underwent 19F MRS at 11.7T, specimens from 4
cholesterol-fed rabbits underwent 19F MRI, specimens
from 3 cholesterol-fed rabbits underwent 19F MRS at 3T
and 11.7T, and specimens from 2 cholesterol-fed rabbits
and 1 healthy control were used for histology.Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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The first phase of the study was designed to establish spe-
cific binding of targeted nanoparticles to integrins
expressed in the diseased valves. It consisted of the follow-
ing experimental groups: a "treatment" group (n = 7)
which received 2.2 mL/kg of αν β3 integrin-targeted per-
fluorocarbon nanoparticles, a control group (n = 6) which
received 2.2 mL/kg of untargeted perfluorocarbon nano-
particles, and a "competition" group (n = 4) in which
nonsignaling safflower nanoparticles (formulated with
safflower oil in place of a fluorine core) were used as a pre-
treatment to establish targeting specificity by competitive
inhibition of binding of a second dose of integrin targeted
perfluorocarbon nanoparticles. These rabbits were pre-
treated with 2.2 mL/kg of ανβ3 integrin-targeted nanopar-
ticles made with a nonsignaling safflower oil core,
followed 2 hours later by 2.2 mL/kg of ανβ3 integrin-tar-
geted perfluorocarbon nanoparticles. Three healthy con-
trol rabbits received 2.2 mL/kg of ανβ3 integrin-targeted
perfluorocarbon nanoparticles. All contrast agents were
injected intravenously into the ear vein through a 22G
catheter.
Two hours after the final injection, the aortic valve leaflets
were excised and preserved in formalin. 19F MR spectros-
copy was performed on these valve leaflets at 11.7T.
In the second phase of the study, the aortic valves of four
cholesterol-fed animals were used for 19F imaging at
11.7T. In each of these animals, ανβ3 integrin-targeted per-
fluorocarbon nanoparticles were administered as
described above. To preserve the anatomic structure of
these valves for imaging, the aortic roots were left partially
intact. Immunohistochemistry was performed in two cho-
lesterol-fed animals and one normal animal to verify the
valvular pathology and display of targeted epitopes. All
procedures were approved by the Washington University
Animal Care Committee.
Nanoparticle formulation
PFC nanoparticles were formulated using previously
described methods [20]. Briefly, the nanoparticle emul-
sions comprised 20% (vol/vol) of either 15-crown-5 ether
(Exfluor Research Corp., Round Rock, TX) or safflower
seed oil (Sigma, #S8281), 2% (wt/vol) of a surfactant
comixture, 1.8% (vol/vol) of glycerol (Sigma, #G9012),
and distilled, deionized water. The surfactant comixture
for the ανβ3 targeted nanoparticles contained 98.9 mole%
of egg phosphatidylcholine (Avanti Polar Lipids Inc., #
840051P), 0.093 mole% peptidomimetic vitronectin
antagonist (Kereos, Inc., St. Louis, MO), and 1.0 mole% of
dipalmitoyl phosphotidylethanolamine (Avanti Polar
Lipids Inc., # 850705). For the nontargeted nanoparticles,
egg phosphatidylcholine and dipalmitoyl phosphoti-
dylethanolamine were proportionally increased to replace
the targeting ligand.
MRI protocol
Ex vivo 19F spectroscopy was performed to determine spe-
cificity of targeting and sensitivity to detection of a fluo-
rine signal. An 11.7T Varian INOVA imaging console
(Varian, Inc., Palo Alto, CA) with an 8 cm diameter hori-
zontal bore was used. Spectra were acquired using a cus-
tom built 4-turn solenoid coil tuned to 470 MHz. A spin
echo pulse sequence was used with TR = 2s, TE = 10ms,
512 signal averages, and a scan time of approximately 20
minutes. A spectrally distinct reference standard consist-
ing of 2 μL of 1% nontargeted perfluoro-octyl-bromide
(PFOB) nanoparticle emulsion was included with each
sample to allow quantitative comparison of spectra.
After feasibility of spectroscopy and specificity of targeting
were established, ex vivo 19F imaging was performed on
four specimens using a custom built 2-turn solenoid coil.
For anatomical localization, proton images showing the
cross-section of the basal aortic root and valve were
acquired using a spin echo imaging sequence with TR = 1s,
TE = 40ms, 0.5 mm slice thickness, 2 × 2 cm2 field of view,
128 × 128 matrix (resulting in 0.16 × 0.16 mm2 in-plane
resolution), and 8 signal averages. After proton acquisi-
tion, the coil was tuned inside the magnet to 470 MHz
and coregistered 19F projection images were acquired
using a similar spin echo imaging sequence with TR =
0.5s, TE = 18ms, 2 × 2 cm2 field of view, 16 × 16 matrix
(resulting in 0.3 × 0.3 mm2 in-plane resolution), and 128
signal averages. Scan time was approximately 30 minutes.
Quantification of binding sites
The relationship between the PFOB and crown ether sig-
nals was defined by acquiring spectra from a series of
phantoms containing varying volumes of PFOB and
crown ether emulsions. Because a given volume of CE has
a stronger signal than a given volume of PFOB, phantoms
were prepared with a fixed 5:1 ratio between PFOB and CE
concentrations. Larger volumes of diluted PFOB were pre-
pared at concentrations of 20%, 10%, 5%, 2.5%, 1.25%,
and 0.625%; corresponding volumes of diluted CE emul-
sion were prepared at concentrations of 4%, 2%, 1%,
0.5%, 0.25%, and 0.125%. Phantoms (44 μL) were pre-
pared containing 2 μL each of diluted PFOB emulsion and
diluted crown ether emulsion, and the balance consisted
of deionized water. Three phantoms were prepared at
each pair of concentrations and spectra were acquired
using the same pulse sequence as above, with 128 signal
averages and scan time of 5 minutes.
Data analysis
Quantitative comparison of spectra was performed using
in-house software created in Matlab (The MathWorks,
Natick, MA) to numerically integrate the area under the
crown ether peak and the area under the largest PFOB
peak (located 8 ppm away), and compute the ratio of inte-Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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grated crown ether signal to integrated PFOB signal. Area
under the peak was used as the metric for quantification
to reduce the influence of noise on the measurements.
These ratios were then normalized to the average value for
control cholesterol-fed animals treated with nontargeted
nanoparticles. One-way Analysis of Variance (ANOVA)
comparison was performed on the mean 19F signals
among the four groups. Post-hoc groupwise testing was
performed using the Tukey-Kramer HSD test. All statistical
analyses were performed using JMP (Version 5.1, SAS
Institute Inc., Cary, NC).
The ratio between CE and PFOB signals, computed as the
pooled average ratio over the phantom data, was used to
calculate the concentration of CE in the rabbit aortic
valves from the known concentration in the reference
standard. The percentage of specifically targeted nanopar-
ticles was estimated based on the difference between the
fluorine signal from the targeted nanoparticles and the
nontargeted nanoparticles (assumed to represent the pro-
portion of nonspecifically trapped nanoparticles). The
total number of nanoparticles present was estimated
based on a nominal particle volume computed from the
measured nominal particle diameter.
Histology and immunohistochemistry
The aortic root was dissected free of the heart with aortic
valve leaflets intact, and frozen in Optimal Cutting Tem-
perature (OCT) medium. All staining was performed on 5
μm transverse frozen sections of the aortic root and valves.
Morphology was determined using routine hematoxylin
and eosin staining. Immunohistochemistry for endothe-
lial cells (CD31 primary antibody against PECAM, JC70A,
DakoCytomation, Carpinteria, CA), neovasculature
(LM609 primary antibody against ανβ3 integrin, Chemi-
con International, Temecula, CA), macrophages (RAM-11
mouse monoclonal anti-rabbit macrophage antibody,
DakoCytomation, Carpinteria, CA), and myofibroblasts
(1A4 primary antibody against α-smooth muscle actin,
Dako, Carpinteria, CA) was performed using a VectaStain®
ABC kit (Novocastra, Newcastle, UK). Images were digi-
tized under 100×–600× power with a Nikon E800
research microscope and a Nikon DXM1200 camera.
Results
Quantification of binding sites
The relationship between CE detected in the aortic valves
and the PFOB reference standards was calibrated using 19F
spectra acquired from three sets of phantoms containing
known amounts of CE and PFOB nanoparticle emulsions.
The ratios of CE to PFOB signal intensities were 5.7 ± 0.49,
5.6 ± 0.29, and 5.3 ± 0.25 for the phantoms containing,
respectively, 2 μL each of 1% CE and 5% PFOB, 0.5% CE
and 2.5% PFOB, and 0.25% CE and 1.25% PFOB. As
expected, a one-way ANOVA showed no significant differ-
ence between the mean value for each set (F-value = 0.48;
P = 0.64). The pooled mean of the ratio of signal between
CE and PFOB was 5.5 ± 0.56.
19F spectroscopic detection of targeted nanoparticles at 
11.7T
The nanoparticle crown ether signal was readily detected
from all samples undergoing fluorine spectroscopy. Rep-
resentative spectra are shown in Figure 1. One-way
ANOVA comparison of the mean 19F signals among the
four groups indicated a significant difference, (F = 11.5, P
< 0.001). The average volume of nanoparticles in valves in
the treatment group receiving targeted nanoparticles was
19.5 ± 2.7 nL,3.5 times higher than the 5.6 ± 1.5 nL
observed in the control group receiving untargeted nano-
particles (p < .01) (Figure 2). The average volume of nan-
oparticles in valves from the competitive inhibition group
was 10.3 ± 2.0 nL, approximately half that of valves from
the treatment group (p < 0.05). Valves from healthy rab-
19F spectra of valves – Representative CE spectra of valve  leaflets from (A) a rabbit treated with targeted nanoparticles  and (B) a rabbit treated with control untargeted nanoparti- cles Figure 1
19F spectra of valves – Representative CE spectra of 
valve leaflets from (A) a rabbit treated with targeted 
nanoparticles and (B) a rabbit treated with control 
untargeted nanoparticles. The PFOB peaks correspond 
to the reference standard included for quantitative compari-
son. Notice the much stronger signal from the valve of the 
rabbit treated with targeted particles (CE/PFOB = 4.6) than 
from the valve of the rabbit treated with nontargeted parti-
cles (CE/PFOB = 2.2).Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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bits treated with targeted nanoparticles contained an aver-
age of 2.3 ± 1.3 nL of nanoparticles, 8.5 times less than
valves of rabbits with aortic valve disease treated with tar-
geted nanoparticles (p < .001); this signal was not signifi-
cantly different from the nanoparticle concentration in
the control group.
In valves of animals treated with targeted nanoparticles,
the estimated volume of nanoparticles present in the valve
was 19.5 ± 2.7 nL, corresponding to 0.11% ± 0.01% of the
total tissue volume. The average concentration of nano-
particles (and hence binding sites) was 1.8 × 1011 ± 0.24 ×
1011 particles per gram of tissue (a total of 7.0 × 108 ± 0.96
× 108 particles in approximately 4 mg of tissue). As control
nanoparticles did not contain a targeting ligand, the nan-
oparticles detected in those tissue samples were likely
trapped or nonspecifically bound. A similar degree of
nonspecific binding is expected for targeted nanoparticles,
so it was estimated that approximately 70% of nanoparti-
cles in the tissue samples containing targeted nanoparti-
cles are specifically bound and approximately 30% are
nonspecifically bound.
19F imaging of targeted nanoparticles
In four specimens, the perfluorocarbon component of tar-
geted nanoparticles in the valve leaflets was successfully
imaged. Co-registered proton and fluorine images were
acquired, and the fluorine image was overlaid onto the
proton image to form a "hot spot" image with anatomical
localization of the fluorine signal (Figure 3). As expected,
the greatest signal occurs at the base of the valve leaflets,
but signal from the body of the leaflets is also visible.
Histological analysis
Histology of transverse sections of the aortic valve exhib-
ited gross thickening and extensive foam cell infiltration
of diseased valve leaflets compared to healthy leaflets,
especially near the base (Figure 4A–C). Non-calcified
bone was observed in the base of one valve leaflet (Figure
4B). Extensive macrophage infiltration was observed in
the diseased valve (Figure 4D) as well as differentiation of
cells into activated myofibroblasts on the aortic endothe-
lial side of the valve (Figure 4E), suggesting an active
inflammatory process. These cells were absent in the nor-
mal valve. Endothelial staining for PECAM confirmed the
presence of abnormal microvessels within the diseased
valve leaflets (Figure 4F), with no such vessels present in a
normal valve. These vessels accumulated near the base of
the valve leaflets, emanating from vascular beds in the
aortic wall, similar to vasa vasorum penetrating into
atherosclerotic plaque under cholesterol drive [21]. Stain-
ing for ανβ3 integrin confirmed that the observed abnor-
mal microvessels have highly upregulated ανβ3 expression
(Figure 4G), and can bind to the targeting ligand on the
nanoparticles. Only minimal ανβ3  expression was
observed in the normal valve (Figure 4H).
Discussion
In this study we demonstrate specific binding of integrin-
targeted nanoparticles to neovasculature in experimental
valve disease, and provide proof of concept for their detec-
tion with magnetic resonance imaging and spectroscopy
methods. Although the presence of angiogenesis in
atherosclerotic plaques in the aorta of this model has been
described previously [15], angiogenesis in the aortic valve
has not been reported. We demonstrate that the model
develops sufficient valvular inflammation and angiogenic
expression of ανβ3 integrins to permit 19F spectroscopy
and imaging ex vivo, and we have illustrated the presence
of angiogenesis by immunohistochemistry. The sensitiv-
ity of this approach for molecular detection of sparse
quantities of inflammatory epitopes in very thin struc-
tures at high field strengths establishes a basis for future
efforts to develop localized spectroscopic methods at clin-
ical field strengths that could be useful for detecting dis-
ease and monitoring therapies.
Quantitative comparison of spectra – Comparison of CE  spectra from the four study groups Figure 2
Quantitative comparison of spectra – Comparison of 
CE spectra from the four study groups. All values are 
nanoliters of emulsion present in the valve, as calculated 
from the 19F MR signal. Note that the valves treated with tar-
geted particles have ~3× the signal of control valves and ~2× 
the signal of valves from the competitive inhibition group. 
Minimal nanoparticle deposition occurs in non-atheroscle-
rotic animals treated with targeted nanoparticles, where no 
angiogenesis (and hence no binding ligands) are present in the 
valve.Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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Inflammation and angiogenesis are a natural part of the
body's wound healing response, but can become patho-
logical in certain conditions, such as atherosclerosis
[21,22] and cancer [23]. Inflammatory tissue components
stimulate formation of neovasculature, which then serves
as a conduit for deployment of cytokines and other
inflammatory molecules, often creating a vicious cycle in
disease evolution. Inflammation and angiogenesis are
both manifest in early valve disease [6-9], which has led
to reassessment of its early pathophysiology, (formerly
regarded as a passive degenerative process). Indeed, early
valve lesions bear striking similarities to early inflamma-
tory atherosclerotic lesions, with infiltration by various
cell types, including macrophages and T-cells, and upreg-
ulation of cytokines, integrins, and cellular adhesion mol-
ecules [5-9].
The ανβ3 integrin is a well described marker for angiogen-
esis [15], and it is upregulated on the lumenal side of neo-
vascular endothelium, but only sparsely expressed on
mature vascular endothelium. The targeting ligand used
in this study is highly specific; it is a peptidomimetic small
molecule which functions as a vitronectin antagonist with
nanomolar Kd values [24]. The fluorine signal from the
valves of rabbits treated with ανβ3-targeted nanoparticles
was more than triple that of the valves of rabbits treated
with untargeted nanoparticles, consistent with the pres-
ence of specific neovasculature targets. Because the nano-
particles are too large (200 nm) to escape even "leaky"
neovasculature [25], it is highly unlikely that other
epitopes on vascular smooth muscle cells or interstitial
inflammatory cells are being targeted. The R1 and R2, 1.31
s-1 and 14.1 s-1, respectively, do not change upon nanopar-
ticle binding [26], ensuring accurate signal comparison
between rabbits treated with targeted and untargeted nan-
oparticles.
One aim of the study was to develop and implement
quantitative techniques to assess the degree of inflamma-
tion in aortic valves. 19F MRS/MRI of aortic valve leaflets
may offer advantages over traditional proton imaging,
due to the unique signal generated by fluorine. Fluorine is
relatively easy to detect by MR, and minimal fluorine
occurs in biological tissues, so a fluorinated contrast agent
gives a unique, directly measurable signal with virtually
no background. This allows data to be acquired at a single
time point and mitigates problems of low contrast-to-
noise ratio inherent in agents used for proton MRI, which
affect water relaxation to generate contrast indirectly, and
hence require paired comparison of pre- and post-contrast
datasets. Acquisition of a single unique signal becomes
especially important when the goal is to detect very sparse
epitopes, as in the present study, because the error intro-
duced by multiple measurements may overwhelm a low
percentage signal change.
Furthermore, because 19F spectroscopy of fluorinated nan-
oparticles is potentially quantitative [16], this technique
may prove useful in estimating concentrations of bound
nanoparticles. These concentrations are theoretically
directly related to the number of molecular binding sites
in the valves. We estimate that, in the rabbits studied, an
average of at least 0.11% of the total valvular tissue vol-
ume is occupied by neovasculature: a small but apprecia-
ble amount that demonstrates the sensitivity of the
measurements. This estimate represents the percentage of
tissue occupied by nanoparticles, approximately 70% spe-
cifically bound and 30% nonspecifically trapped due to
the endothelial permeability and retention (EPR) effect,
19F imaging of the aortic valve – Coregistered proton (left) and fluorine (center) images of an aortic valve at 11.7T Figure 3
19F imaging of the aortic valve – Coregistered proton (left) and fluorine (center) images of an aortic valve at 
11.7T. At far right, the fluorine image is false-colored and overlaid on the proton image, showing strong signal at the base of 
the valve leaflets, as well as signal from the body of the leaflets.Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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Histological comparison of diseased and normal aortic valve leaflets – All scale bars are 50 μm in length Figure 4
Histological comparison of diseased and normal aortic valve leaflets – All scale bars are 50 μm in length. (A, B): 
Hematoxylin & Eosin shows thickening and foam cell accumulation in diseased valve leaflets compared to normal valve leaflet 
(C). (B) shows bone formation at the base of a diseased aortic valve leaflet. The diseased valve leaflet contains extensive mac-
rophage infiltration (D) and smooth muscle actin-positive myofibroblasts (E). Endothelial staining (PECAM) shows microvascu-
lature within diseased valve leaflet (F). Macrophage, smooth muscle actin, and PECAM stains were negative in normal aortic 
valve (data not shown). ανβ3 integrin stain shows angiogenesis in diseased valve leaflet with highly upregulated expression of 
ανβ3 (G), while there is minimal expression in the healthy valve leaflet (H).Journal of Cardiovascular Magnetic Resonance 2008, 10:43 http://www.jcmr-online.com/content/10/1/43
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and likely represents a lower bound on the proportion of
valve tissue occupied by neovasculature. If shown to be
applicable in vivo on larger samples of valve tissue, this
approach could prove useful for quantitative longitudinal
evaluation of disease progression.
We have additionally demonstrated the feasibility of 19F
imaging at 11.7T. A projection image of the valve was
acquired with 0.3 × 0.3 mm2 in-plane resolution and
approximately 20 minute scan time. The images show het-
erogeneous distribution of fluorine signal corresponding
to neovasculature. The preponderance of signal occurs at
the edges of the valve leaflets, consistent with histological
observation of the location of neovasculature, which typ-
ically emanates from vascular beds in the aortic root.
We have recently reported several results illustrating fluo-
rine detection at 1.5T for both molecular imaging and
angiography [27,28], and clinical scanners are being
developed at increasing field strengths (3T and 7T), which
will provide even greater sensitivity.
Limitations
The data for this study were acquired ex vivo as a first step
to demonstrate that: 1) angiogenesis occurs within the
valve leaflets under experimental conditions, 2) is detect-
able by MR fluorine spectroscopy, and 3) holds potential
for imaging and quantification. The study was performed
on formalin-fixed tissue, which might affect local 1H sig-
nals but is unlikely to affect 19F measurements since the
perfluorocarbons are chemically inert and the lipid com-
ponents of the particle unreactive. The techniques devel-
oped might be extended to the in vivo situation to enable
noninvasive detection of angiogenesis in aortic valves. We
have recently acquired in vivo 19F images under other con-
ditions with a resolution of 1 × 1 × 3 mm3 in 2–2.5 min-
utes [28]. Various approaches for localized spectroscopy
can be applied to isolate the valve, along with cardiac and
respiratory gating to compensate for bulk motion. Nano-
particle dosage and time between injection and imaging
are two parameters which would require optimization in
an in vivo situation; this was beyond the scope of the cur-
rent study, designed to demonstrate proof of principle.
Immunohistochemistry was obtained from separate spec-
imens than those which underwent MRI, so the presence
of a direct correlation of angiogenesis and 19F signal could
not be tested. However, the in vivo competition data dem-
onstrates targeting specificity.
Furthermore, a correlation between the extent of angio-
genesis and clinical diagnosis of disease severity has been
established in human patients with mild to moderate
valve disease [9].
Conclusion
We suggest that these data point the way toward the use of
molecular targeted contrast agents for elucidating certain
fundamental pathological processes underlying valvular
disease. Detection and monitoring strategies based on the
underlying pathology may prove more effective than
exclusive reliance on symptoms, signs, or traditional late
stage imaging techniques for diagnosis and treatment. The
question of what to image as a meaningful biomarker of
early valve disease is yet unclear: a variety of molecules
(integrins, adhesion molecules, signaling molecules, etc.)
and cell types (myofibroblasts, T cells, etc.) are potentially
targetable. Indeed, a variety of agents may be complemen-
tary in teasing out complex pathobiology. Macrophages
have been correlated with disease activity [27], and are
easily identified with constructs such as iron oxide nano-
particles. However, agents targeting neovasculature could
also be quite useful since it has been shown that neovas-
cular development is required for atherosclerotic lesion
evolution [29]. We have demonstrated tools to quantify
angiogenesis in aortic valve leaflets, which may permit
more detailed study of its role in the progression of valvu-
lar lesions.
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